Payers are exerting increasing influence over oncology through tighter utilization management, formulary controls, and reimbursement strategies aimed at managing rapidly rising cancer drug spend. This paper explores how tools such as prior authorization, site-of-care redirection, and pathway enforcement are reshaping treatment access and prescribing behavior, with implications for both providers and patients.
